Autopsies find coronavirus in the brain, multiple organs


Experts had predicted as much, so it wasn’t a surprise that COVID hospitalizations rose after Christmas, especially among people 70 and above. The good news is that the numbers are still 70% below last January’s at the peak of the first omicron surge. Perhaps more worrisome is the sudden rise of the XBB.1.5 subvariant, which the World Health Organization calls the most transmissible to date. The surge of XBB.1.5 prompted a Twitter thread from White House COVID-19 coordinator Dr. Ashish Jha on what’s known about the strain, but UCSF’s Dr. Bob Wachter doesn’t seem hugely worried about it. 

Infectious diseases group slams testing rules for Chinese travelers

The Infectious Diseases Society of America, an advocacy group made up of about 12,000 physicians and experts, has issued a letter condemning the U.S. government’s new policy of requiring pre-flight COVID-19 testing for all travelers from China. In an open letter posted online Thursday, the group said the rule “will likely have limited impact on transmission and will not provide the necessary data to fully assess the increasing number of cases globally. In addition, the policy could unintentionally fuel anti-Asian bias and xenophobia.”

The members advocate that the Biden Administration instead roll out broader testing strategies that are not limited by geography, as well as other measures that may better help prevent transmission of the virus. “As COVID-19 and other respiratory viruses continue to affect our communities and strain hospitals this winter, it is critical that we continue to protect ourselves and others by practicing basic public health precautions: stay home when ill, get all recommended vaccinations and boosters, and mask when appropriate,” said the letter co-authored by Carlos del Rio, the president of Infectious Diseases Society of America.

Autopsies find virus in the brain, multiple organs

The coronavirus is capable of replicating within the heart, lymph node, small intestine, adrenal gland, brain, and many other tissues, according to a peer-reviewed study published in the journal Nature. Researchers from the National Institute of Health studied the autopsies of 44 people who died of COVID-19 and found viral fragments in 79 of the 85 locations of the body they reviewed in the patients. The authors said their findings represent “the most comprehensive analysis to date of the cellular tropism, quantification, and persistence of SARS-CoV-2 across the human body, including the brain.” They added that the study proves the virus hits the body at a cellular level, debunking the notion that it only lingers in the respiratory system. “Our results show that although the highest burden of SARS-CoV-2 is in respiratory tissues, the virus can disseminate throughout the entire body.”

XBB.1.5 driving up hospitalizations on East Coast

The pace of new COVID-19 hospital admissions is rapidly rising in regions where XBB.1.5 has become dominant. The latest omicron offshoot has been labeled the most infectious coronavirus subvariant to date and made up about 75% of new sequenced cases on the East Coast last week, according to data published last Friday by the U.S. Centers for Disease Control and Prevention. The seven-day moving average of hospital admissions has nearly doubled in a month across the region, with some areas seeing a 74% increase in patients in that period, according to federal data. Admission rates for older adults are approaching those seen during the 2021 winter peak. Based on national ensemble models, the CDC this week forecast that hospitalization rates nationwide for all ages “will remain stable or have an uncertain trend,” but XBB.1.5 could upend those predictions.

Virus deaths, hospitalizations climb across the state following holiday reprieve

After a brief dip over the holidays, California’s COVID-19 trends appear to be in flux heading into the new year. The state is tallying a daily average of 6,224 new cases as of Jan. 3, down from an average of 6,772 daily cases reported on Dec. 27. But the statewide test positive rate climbed to 12.6% from 11.9% over the same period. The average of COVID-19 deaths rose to 34 per day from an average of 27 per day reported in the prior week, and 22 deaths a day for the week ending Nov. 27. Hospitalizations are also edging up again, with California reporting 4,547 admissions on Wednesday, comparable with previous weeks and up 13% from a month earlier.

Beds run out at Beijing hospital as virus spreads

At the Chuiyangliu hospital in the east of Beijing on Thursday, signs of the COVID-19 outbreak stretching public health facilities in the world’s most populous nation were on full display, the Associated Press reports. Beds ran out by midmorning at the packed hospital, even as ambulances brought more people in. Hard-pressed nurses and doctors rushed to take information and triage the most urgent cases. The crush of people seeking hospital care follows China’s abandonment of its most severe pandemic restrictions last month after nearly three years of lockdowns, travels bans and school closures that weighed heavily on the economy and prompted unusual street protests in a country that quashes political dissent. The outbreak appears to have spread the fastest in densely populated cities. Now, authorities are concerned as it reaches smaller towns and rural areas with weaker health care systems. Several local governments began asking people Thursday not to make the trip home for the upcoming Lunar New Year holiday, signaling lingering worry around opening up.

Promising finding on early treatment against long COVID

Researchers at the University of Minnesota have discovered that the oral diabetes medication metformin may cut the risk of developing the persistent symptoms of long COVID by 42% when taken for two weeks within 3 days of a confirmed coronavirus infection. In the randomized, multi-site trial composed of 1,125 adults between the ages 30 to 85 who were classified as being overweight, the researchers compared the effectiveness of three oral medications — metformin, antidepressant fluvoxamine, and antiparasitic drug ivermectin, which has previously been discounted as a viable treatment option for COVID-19. The first option was the only one that proved effective. “Further clinical trials are warranted to assess whether there is synergy with other treatments, such as nirmatrelvir in vaccinated populations or in those with prior COVID-19,” the authors wrote in the study. “Fluvoxamine and ivermectin did not decrease the development of long COVID, which is consistent with outcomes in the first 14 days of the trial.”

Hospitalizations up 17% nationwide following Christmas

New admissions of patients with confirmed COVID-19 in the U.S. rose 17% compared with the previous seven-day average, according to updated figures from the U.S. Centers for Disease Control and Prevention. The overall seven-day average of new daily admissions for all age groups was 6,483 as of Monday, up from a prior average of 5,541 for the week ending Dec. 26. It’s worth noting that the current numbers are still 70% below their peak last January.




Click Here For This Articles Original Source.

Leave a Reply

Your email address will not be published. Required fields are marked *